On January 22 Huntington’s disease advocacy organizations delivered two petitions to the U.S. Food and Drug Administration (FDA), demanding that the agency reverse its rollback on uniQure’s application for its HD gene therapy.
Want to keep yourself up to date with the latest news from At Risk for Huntington's Disease?
Subscribe using the "Follow" button below and we provide you with customized updates, via topic or tag, that get delivered to your email address, your smartphone or on your dedicated news page on follow.it.
You can unsubscribe at any time painlessly.
Title of At Risk for Huntington's Disease: "At Risk for Huntington's Disease"
